Efg Asset Management (Americas) Corp. Fate Therapeutics Inc Transaction History

Efg Asset Management (Americas) Corp.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 13, 2022	SELL	$17.78 - $42.39 $867,735 - $2.07 Million	-48,804 Closed	0 $0
Q1 2022 May 05, 2022	BUY	$29.67 - $60.28 $66,579 - $135,268	2,244 Added 4.82%	48,804 $1.89 Million
Q4 2021 Jan 24, 2022	BUY	$47.84 - $64.34 $348,801 - $469,102	7,291 Added 18.57%	46,560 $2.72 Million
Q3 2021 Oct 22, 2021	BUY	$59.27 - $95.73 $27,619 - $44,610	466 Added 1.2%	39,269 $2.33 Million
Q2 2021 Jul 23, 2021	BUY	$67.25 - $92.52 $305,315 - $420,040	4,540 Added 13.25%	38,803 $3.37 Million
Q1 2021 Apr 09, 2021	BUY	$72.16 - $117.4 $2.47 Million - $4.02 Million	34,263 New	34,263 $2.83 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.